Studies immune cells in tumors and blood during adoptive cell therapy
Examines immune cells from tumor, blood and marrow in people with solid or blood cancers.
Plain-language title generated from the registry record
Registry title: An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors
Key facts
- Where
- Villejuif, FranceSee the site
Where in France
- Gustave Roussy Cancer Campus, Grand ParisVillejuif, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Gustave Roussy, Cancer Campus, Grand Paris
- Trial code
- NCT05481502
- Record updated
- 6 November 2026
- Original description
This is a study to explore the phenotypic and transcriptional changes of different cellular components in the tumor following the injection of somatic cell therapy drugs.Read full original descriptionShow less
A Prospective Trial to Evaluate Immune Determinants of the Response and the Toxicity to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors
This is a study to explore the phenotypic and transcriptional changes of different cellular components in the tumor following the injection of somatic cell therapy drugs.
The second objective is to explore phenotypic and transcriptional changes of different cellular components in blood and bone marrow following injection of somatic cell therapy drugs.Then correlate the phenotypic and transcriptional profile of different tumor, blood and bone marrow immune populations with clinical response and/or toxicity. And to finish this study is designed in order to identify a phenotypic, transcriptional and epigenetic profile of intra-tumoral adoptive cells and correlate this profile with clinical response and/or toxicity.
Inclusion: Patient affiliated to a social security regimen; Tumor lesion accessible to core biopsies; Patient who is fully informed, able to comply with the protocol and who signed the informed consent; Pediatric patients > than 2 years old can be included; No restriction about the Eastern Cooperative Oncology Group (ECOG) status.
Exclusion: Coagulation abnormality prohibiting a biopsy (but patients can still give their consent for blood and bone marrow samples); Tumor lesion not accessible to core biopsies; Pregnant or nursing women cannot participate in this study.